Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer

PURPOSE: Studies comparing the effect of aromatase inhibitor (AI) and tamoxifen use on cardiovascular disease (CVD) risk factors in hormone-receptor positive breast cancer (BC) survivors report conicting results. We examined associations of endocrine therapy use with incident diabetes, dyslipidemia,...

Descripción completa

Detalles Bibliográficos
Autores principales: Rillamas-Sun, Eileen, Kwan, Marilyn L., Carlos, California, Cheng, Richard, Neugebauer, Romain, Rana, Jamal S., Nguyen-Huynh, Mai, Shi, Zaixing, Laurent, Cecile A., Lee, Valerie S., Roh, Janise M., Huang, Yuhan, Shen, Hanjie, Hershman, Dawn L., Kushi, Lawrence H., Greenlee, Heather
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055634/
https://www.ncbi.nlm.nih.gov/pubmed/36993531
http://dx.doi.org/10.21203/rs.3.rs-2675372/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055634/
https://www.ncbi.nlm.nih.gov/pubmed/36993531
http://dx.doi.org/10.21203/rs.3.rs-2675372/v1

Ejemplares similares